PXPR007 sgCIC-2 Citations (3)

Originally described in: ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.
Wang B, Krall EB, Aguirre AJ, Kim M, Widlund HR, Doshi MB, Sicinska E, Sulahian R, Goodale A, Cowley GS, Piccioni F, Doench JG, Root DE, Hahn WC Cell Rep. 2017 Feb 7;18(6):1543-1557. doi: 10.1016/j.celrep.2017.01.031. PubMed Journal

---

Articles Citing PXPR007 sgCIC-2

Articles
Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma. Lin YK, Wu W, Ponce RK, Kim JW, Okimoto RA. Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20776-20784. doi: 10.1073/pnas.2009137117. Epub 2020 Aug 11. PubMed
Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer. Kim JW, Luck C, Wu W, Ponce RK, Lin YK, Gupta N, Okimoto RA. Cell Rep. 2022 Oct 4;41(1):111443. doi: 10.1016/j.celrep.2022.111443. PubMed
The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression. Gupta N, Song H, Wu W, Ponce RK, Lin YK, Kim JW, Small EJ, Feng FY, Huang FW, Okimoto RA. Elife. 2022 Nov 16;11:e77072. doi: 10.7554/eLife.77072. PubMed

If you have published an article using this material, please email us at to have your article added to this page.